Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rovalpituzumab Tesirine in DLL3-Expressing Advanced Solid Tumors
NCT02709889Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Sep 2016
- Primary completion
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rovalpituzumab tesirine in Malignant Melanoma (MM), Medullary Thyroid Cancer (MTC), glioblastoma (GBM), large cell neuroendocrine carcinoma (LCNEC), neuroendocrine prostate cancer (NEPC), sponsored by AbbVie Inc.. Started Sep 2016; status: terminated.
02
Drugs
rovalpituzumab tesirine
03
Conditions
Malignant Melanoma (MM)Medullary Thyroid Cancer (MTC)glioblastoma (GBM)large cell neuroendocrine carcinoma (LCNEC)neuroendocrine prostate cancer (NEPC)
Beyond the preview
Go deeper on NCT02709889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02709889.